Stock Plunge for Bayer as Analysts Assess Recent Dramatic Drop
In the world of stock market investments, Bayer AG's shares (BAYN) have been a subject of debate among analysts. Despite the lack of buy recommendations, the average target price of 30.68 euros still suggests an upside of 48%.
Currently, no analysts are advocating for the purchase of Bayer's shares, with 10 hold recommendations. This mistrust of Bayer's stock is evident in the chart, as demonstrated by the recent 14.5% decline on Tuesday, which brought the stock close to the 20 euro mark, a level not seen in 20 years. This decline has led to concerns among investment banks and analysts.
Market observers, including Goldman Sachs, Stifel, and UBS, have expressed negative sentiments following Bayer's stock crash, citing missed consensus estimates and a negative outlook. Goldman Sachs and Barclays have both cut their target prices for Bayer, with Goldman Sachs lowering its target from 30 euros to 27 euros, and Barclays reducing its target from 26 euros to 22 euros.
However, if Bayer manages to defend the 20 euro mark, analysts generally expect the stock to recover and perform well after its recent crash. According to forecasts, Bayer's stock is expected to rise to around €26.85 by the end of 2025 and reach approximately €34.46 by the end of 2029.
In the short term, Bayer's stock was upgraded to a Strong Buy candidate as of early July 2025, with analysts projecting a potential 28.65% gain over the next three months. HSBC has also upgraded Bayer from Hold to Buy, setting a price target of around €32. This upgrade correlates with rising earnings estimates, pointing to improving underlying business fundamentals that could drive stock price appreciation.
Overall, analysts expect Bayer's stock to rebound with significant gains over the next months to years, driven by improving earnings prospects and positive market sentiment following its recent downturn. For further information, readers are advised to explore the article "Bayer: Is this the end for the stock?"
It is essential to note that Bernd Förtsch, the CEO and majority shareholder of Börsenmedien AG, has direct and indirect positions in Bayer, potentially benefiting from the price development of the stock. As always, investors are advised to conduct their own due diligence before making investment decisions.
For those interested in exploring alternative investment opportunities, the article "These cryptocurrencies are now unstoppable: Bitcoin, Doge, Solana, and more - should you buy now?" offers insights into the crypto market. The chart for Bayer's stock performance can be found on TradingView.
Investors may find interest in Bayer's shares (BAYN), despite analysts generally not advocating for their purchase, as the average target price of 30.68 euros suggests an upside of 48%. However, concerns have arisen due to the recent 14.5% decline, with Bayer's stock being close to the 20 euro mark, a level not seen in 20 years.
